跳至主要内容
临床试验/NCT00135993
NCT00135993已完成3 期

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

UCB Pharma1 个研究点 分布在 1 个国家目标入组 811 人开始时间: 2005年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
UCB Pharma
入组人数
811
试验地点
1
主要终点
IRLS sum score and CGI Item 1 score severity of illness

研究概览

简要总结

Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial.

The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine.

Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Idiopathic restless legs syndrome

排除标准

  • History of sleep disturbances

结局指标

主要结局

IRLS sum score and CGI Item 1 score severity of illness

时间窗: From Baseline at the end of the Maintenance Period

次要结局

  • IRLS Responder: A responder is a subject with a decrease of ≥50% in IRLS sum score(From Baseline at the end of the Maintenance Period)
  • CGI Item 1 Responder: A responder is defined as a subject with a decrease of ≥50% in CGI Item 1(From Baseline at the end of the Maintenance Period)
  • Changes in CGI Items 2-3 (continuous) during the Maintenance Period; Change from Baseline in RLS-6 Rating Scales at the end of the Maintenance Period

研究者

发起方
UCB Pharma
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验